ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL535
CHEMBL535
Compound Name SUNITINIB
ChEMBL Synonyms SU-11248 | SUNITINIB | Sutent | SUNITINIB MALATE
Max Phase 4 (Approved)
Trade Names Sutent
Molecular Formula C22H27FN4O2

Additional synonyms for CHEMBL535 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C
Standard InChI InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25 ...
Download InChI
Standard InChI Key WINHZLLDWRZWRT-ATVHPVEESA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • Orange Book
  • Patent Bioactivity Data
  • PubChem BioAssays
  • Sanger Institute Genomics of Drug Sensitivity in Cancer
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL535

Molecule Features

CHEMBL535 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Macrophage colony stimulating factor receptor inhibitor Macrophage colony stimulating factor receptor DailyMed
Platelet-derived growth factor receptor inhibitor Platelet-derived growth factor receptor DailyMed
Stem cell growth factor receptor inhibitor Stem cell growth factor receptor DailyMed
Tyrosine-protein kinase receptor FLT3 inhibitor Tyrosine-protein kinase receptor FLT3 DailyMed
Tyrosine-protein kinase receptor RET inhibitor Tyrosine-protein kinase receptor RET DailyMed
Vascular endothelial growth factor receptor inhibitor Vascular endothelial growth factor receptor DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
BREAST NEOPLASMSD001943EFO:0000305BREAST CARCINOMA3ClinicalTrials
CARCINOMA, RENAL CELLD002292EFO:0000640PAPILLARY RENAL CELL CARCINOMA4ClinicalTrials
NEUROENDOCRINE TUMORSD018358EFO:1000045PANCREATIC NEUROENDOCRINE TUMOR4DailyMed
ADENOCARCINOMAD000230EFO:0000228ADENOCARCINOMA2ClinicalTrials
CARCINOMAD002277EFO:0000313CARCINOMA2ClinicalTrials
CARCINOMA, SQUAMOUS CELLD002294EFO:0000181HEAD AND NECK SQUAMOUS CELL CARCINOMA2ClinicalTrials
LUNG NEOPLASMSD008175EFO:0001071LUNG CARCINOMA2ClinicalTrials
PANCREATIC NEOPLASMSD010190EFO:0002618PANCREATIC CARCINOMA2ClinicalTrials
PROSTATIC NEOPLASMSD011471EFO:0000673PROSTATE ADENOCARCINOMA2ClinicalTrials
URINARY BLADDER NEOPLASMSD001749EFO:0000292BLADDER CARCINOMA2ClinicalTrials
ClinicalTrials
KIDNEY NEOPLASMSD007680EFO:0003865KIDNEY NEOPLASM3ClinicalTrials
MULTIPLE MYELOMAD009101EFO:0001378MULTIPLE MYELOMA2ClinicalTrials
CARCINOMA, HEPATOCELLULARD006528EFO:0000182HEPATOCELLULAR CARCINOMA3ClinicalTrials
ClinicalTrials
GASTROINTESTINAL STROMAL TUMORSD046152Orphanet:44890GASTROINTESTINAL STROMAL TUMOR4DailyMed
ClinicalTrials
ClinicalTrials
SARCOMAD012509EFO:0000691SARCOMA2ClinicalTrials
SARCOMA, KAPOSID012514EFO:0000558KAPOSI'S SARCOMA2ClinicalTrials
MELANOMAD008545EFO:0000756MELANOMA2ClinicalTrials
NEOPLASMSD009369EFO:0000311CANCER4ClinicalTrials
ClinicalTrials
OVARIAN NEOPLASMSD010051EFO:0001075OVARIAN CARCINOMA2ClinicalTrials
SMALL CELL LUNG CARCINOMAD055752EFO:0000702SMALL CELL LUNG CARCINOMA2ClinicalTrials
STOMACH NEOPLASMSD013274EFO:0003897STOMACH NEOPLASM2ClinicalTrials
CARCINOMA, RENAL CELLD002292EFO:0002890RENAL CARCINOMA4ClinicalTrials
ClinicalTrials
PROSTATIC NEOPLASMSD011471EFO:0000196METASTATIC PROSTATE CANCER2ClinicalTrials
LYMPHOMAD008223EFO:0000574LYMPHOMA2ClinicalTrials
LYMPHOMA, LARGE B-CELL, DIFFUSED016403EFO:0000403DIFFUSE LARGE B-CELL LYMPHOMA2ClinicalTrials
VON HIPPEL-LINDAU DISEASED006623Orphanet:892VON HIPPEL-LINDAU DISEASE1ClinicalTrials
CARCINOMA, RENAL CELLD002292EFO:0000349CLEAR CELL RENAL CARCINOMA4ClinicalTrials
ClinicalTrials
MELANOMAD008545EFO:0002617METASTATIC MELANOMA2ClinicalTrials
PROSTATIC NEOPLASMSD011471EFO:0001663PROSTATE CARCINOMA2ClinicalTrials
ClinicalTrials
BREAST NEOPLASMSD001943EFO:0003869BREAST NEOPLASM3ClinicalTrials
ClinicalTrials
CARCINOMA, NON-SMALL-CELL LUNGD002289EFO:0003060NON-SMALL CELL LUNG CARCINOMA3ClinicalTrials
ClinicalTrials
PERITONEAL NEOPLASMSD010534EFO:1001100PERITONEAL NEOPLASM2ClinicalTrials
URINARY BLADDER NEOPLASMSD001749EFO:0000294BLADDER TUMOR2ClinicalTrials
ASCITESD001201HP:0001541ASCITES2ClinicalTrials
CARCINOMA, RENAL CELLD002292EFO:0000681RENAL CELL CARCINOMA4ClinicalTrials
DailyMed
ClinicalTrials
CHOLANGIOCARCINOMAD018281EFO:0005221CHOLANGIOCARCINOMA2ClinicalTrials
GLIOBLASTOMAD005909EFO:0000519GLIOBLASTOMA MULTIFORME2ClinicalTrials
NEOPLASMSD009369EFO:0000616NEOPLASM4ATC
ClinicalTrials
THYMOMAD013945EFO:1000581THYMOMA2ClinicalTrials
THYROID NEOPLASMSD013964EFO:0002892THYROID CARCINOMA2ClinicalTrials
ESOPHAGEAL NEOPLASMSD004938EFO:0002916ESOPHAGEAL CARCINOMA2ClinicalTrials
MESOTHELIOMAD008654EFO:0000588MESOTHELIOMA2ClinicalTrials

Clinical Data

ClinicalTrials.gov SUNITINIB
The Cochrane Collaboration SUNITINIB

Metabolites for CHEMBL535

Open in full screen

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL535. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL1913 Platelet-derived growth factor receptor beta Homo sapiens 1.000
CHEMBL2007 Platelet-derived growth factor receptor alpha Homo sapiens 1.000
CHEMBL2041 Tyrosine-protein kinase receptor RET Homo sapiens 1.000
CHEMBL1936 Stem cell growth factor receptor Homo sapiens 1.000
CHEMBL2349 Phosphorylase kinase gamma subunit 2 Homo sapiens 1.000
CHEMBL2964 Dual specificity mitogen-activated protein kinase kinase 2 Homo sapiens 1.000
CHEMBL3125 Ribosomal protein S6 kinase alpha 4 Homo sapiens 1.000
CHEMBL2073 Tyrosine-protein kinase YES Homo sapiens 1.000
CHEMBL4147 CaM kinase II alpha Homo sapiens 1.000
CHEMBL1955 Vascular endothelial growth factor receptor 3 Homo sapiens 1.000
CHEMBL5469 Protein tyrosine kinase 2 beta Homo sapiens 1.000
CHEMBL4045 AMP-activated protein kinase, alpha-1 subunit Homo sapiens 1.000
CHEMBL3650 Fibroblast growth factor receptor 1 Homo sapiens 1.000
CHEMBL1841 Tyrosine-protein kinase FYN Homo sapiens 1.000
CHEMBL5084 Casein kinase I isoform gamma-3 Homo sapiens 1.000
CHEMBL3831 MAP/microtubule affinity-regulating kinase 2 Homo sapiens 1.000
CHEMBL3935 Serine/threonine-protein kinase Aurora-C Homo sapiens 1.000
CHEMBL5699 Serine/threonine-protein kinase SIK2 Homo sapiens 1.000
CHEMBL2543 Casein kinase I gamma 2 Homo sapiens 1.000
CHEMBL3829 CaM kinase II gamma Homo sapiens 1.000



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL1913 Platelet-derived growth factor receptor beta Homo sapiens 1.000
CHEMBL2041 Tyrosine-protein kinase receptor RET Homo sapiens 1.000
CHEMBL3650 Fibroblast growth factor receptor 1 Homo sapiens 1.000
CHEMBL2007 Platelet-derived growth factor receptor alpha Homo sapiens 1.000
CHEMBL1936 Stem cell growth factor receptor Homo sapiens 1.000
CHEMBL2349 Phosphorylase kinase gamma subunit 2 Homo sapiens 1.000
CHEMBL3516 Vascular endothelial growth factor receptor 1 Mus musculus 1.000
CHEMBL2073 Tyrosine-protein kinase YES Homo sapiens 1.000
CHEMBL3125 Ribosomal protein S6 kinase alpha 4 Homo sapiens 1.000
CHEMBL1841 Tyrosine-protein kinase FYN Homo sapiens 1.000
CHEMBL2493 CaM kinase I alpha Homo sapiens 1.000
CHEMBL4147 CaM kinase II alpha Homo sapiens 1.000
CHEMBL4175 Tyrosine-protein kinase CTK Homo sapiens 1.000
CHEMBL2964 Dual specificity mitogen-activated protein kinase kinase 2 Homo sapiens 1.000
CHEMBL5284 CaM-kinase kinase beta Homo sapiens 1.000
CHEMBL5608 NT-3 growth factor receptor Homo sapiens 1.000
CHEMBL5650 BR serine/threonine-protein kinase 1 Homo sapiens 1.000
CHEMBL5084 Casein kinase I isoform gamma-3 Homo sapiens 1.000
CHEMBL5627 Leukocyte tyrosine kinase receptor Homo sapiens 1.000
CHEMBL4045 AMP-activated protein kinase, alpha-1 subunit Homo sapiens 1.000

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
398.5 398.2118 3 7 77.23 BASE


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
3 3 0 6 3 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
11.7 9.09 2.27 .44 2 29 0.63

Structural Alerts

There are 4 structural alerts for CHEMBL535. To view alerts please click here.

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 - ANTINEOPLASTIC AGENTS
L01X - OTHER ANTINEOPLASTIC AGENTS
L01XE - Protein kinase inhibitors
L01XE04 - sunitinib

ChemSpider ChemSpider:WINHZLLDWRZWRT-ATVHPVEESA-N
DailyMed sunitinib malate
PubChem SID: 124893176 SID: 26758053 SID: 50100120
Wikipedia Sunitinib

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL535



BindingDB 4814
Brenda 127384 7646 40342 25420
ChEBI 38940
DrugBank DB01268
DrugCentral 2544
eMolecules 23296409 27524016
FDA SRS V99T50803M
Guide to Pharmacology 5713
Human Metabolome Database HMDB0015397
IBM Patent System E15A9C477969D7725F2513D18EAF49DF
LINCS LSM-42800
Nikkaji J1.942.549E J2.036.576E
PDBe B49
PharmGKB PA162372840
PubChem 5329102
PubChem: Thomson Pharma 14830382
SureChEMBL SCHEMBL8081
ZINC ZINC000003964325

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/WINHZLLDWRZWRT-ATVHPVEESA-N spacer
spacer